News | Stents Drug Eluting | January 08, 2016

Stentys Completes Enrollment of MiStent Randomized Trial Against Xience

DESSOLVE III clinical trial enrolled 1,400 “all-comers” patients, with primary endpoint of non-inferiority comparison of target lesion failure

January 8, 2016 — In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical trial will compare the MiStent SES sirolimus eluting absorbable polymer coronary stent system to Abbott’s Xience stent.

The MiStent SES is a balloon-expandable stent designed to improve long-term clinical outcome of patients treated with conventional “workhorse” stents. The device features Crystalline Sirolimus technology, where thousands of microscopic drug crystals slowly dissolve in the surrounding tissue after absorption of the polymer carrier. This allows for a gradual, linear and much longer elution of sirolimus than with other competitive stents, hence reducing vessel over-scarring.

With 2 percent re-intervention rate (target lesion revascularization) at three-year follow-up in previous clinical trials, MiStent SES was shown to be superior to Xience in a retrospective propensity analysis presented by Alexandra Lansky, M.D., New Haven, Conn., during the last EuroPCR conference in Paris.

DESSOLVE III is a prospective, balanced, randomized, controlled, single-blind, multi-center study comparing clinical outcomes between MiStent SES and Xience in a “real world, all-comers” patient population of 1,400 patients in 20 hospitals in Europe. Patients in the trial suffered from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia or acute coronary syndrome, and qualified for percutaneous coronary interventions. The primary endpoint is a non-inferiority comparison of target lesion failure (TLF) of the MiStent SES group versus the Xience group at 12 months post-procedure.

MiStent SES has already received CE Marking. Stentys is MiStent exclusive distributor worldwide, except in the United States, Canada, China, South Korea and Japan, and is currently conducting a controlled launch in select countries in Europe, Middle East and Asia.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init